

LUGPA Global Prostate Cancer Congress

WHERE EVIDENCE MEETS PRACTICE

Grand Hyatt Deer Valley | Park City, Utah

January 9-12, 2027

Program Chair: E. David Crawford, MD

Program Co-Chairs: Scott Sellinger, MD, and David Morris, MD

Saturday, January 9, 2027

*Please note: Topics and Speakers are subject to change.

Time	Program
5:00-7:00 p.m.	Meeting Registration / Information
6:00-7:00 p.m.	Welcome Reception in the Exhibit Hall

Sunday, January 10, 2027

Time	Program
6:00 a.m.-3:30 p.m.	Meeting Registration / Information
6:00-6:30 a.m.	Coffee in the Exhibit Hall
6:30-6:45 a.m.	Welcome, Introductions, Meeting Format, and Slido Instructions E. David Crawford, MD
6:45-7:45 a.m.	SESSION 1: PSA SCREENING AND DIAGNOSTICS - IS SCREENING STILL BROKEN OR FINALLY FIXED? MODERATOR: E. David Crawford, MD
6:45-6:48 a.m.	Slido Questions and Audience Baseline Polling
6:48-7:03 a.m.	SOA: Is Screening Still Broken - or Finally Fixed? E. David Crawford, MD
7:03-7:15 a.m.	AUA Update and Screening/PSA Guidelines: What Is New and What Still Needs to Change? Eugene Y. Rhee, MD
7:15-7:23 a.m.	What Have the New Global Screening Trials Taught Us? Jonathan Henderson, MD
7:23-7:31 a.m.	Which Molecular Markers Actually Change Clinical Decisions in 2027? Jason Hafron, MD
7:31-7:45 a.m.	Interactive Patient Cases, Panel Discussion, Abstracts, and Monday Morning Practice Change Discussion Leader: E. David Crawford, MD
7:45-8:45 a.m.	Industry Breakfast Symposium-Sponsored by: AstraZeneca Suggested alignment: early detection, risk stratification, biomarkers, imaging, or treatment selection
8:45-9:15 a.m.	Exhibit Hall
9:15-10:30 a.m.	SESSION 2: ACTIVE SURVEILLANCE IN 2027 - ARE WE FINALLY GETTING IT RIGHT? MODERATOR: Sagar Patel, MD
9:15-9:20 a.m.	Slido Questions and Audience Baseline Polling
9:20-9:35 a.m.	SOA: Active Surveillance in Favorable Intermediate-Risk Prostate Cancer James Eastham, MD
9:35-9:43 a.m.	What Is Good Risk Stratification in 2027? Matthew Cooperberg, MD
9:43-9:51 a.m.	PSMA PET and MRI in the Prebiopsy and Postbiopsy Workup Sherif Gamie, MD
9:51-9:59 a.m.	When Can We Safely De-intensify Active Surveillance? Gennady Bratslavsky, MD
9:59-10:07 a.m.	TULSA: Is It Truly Different From Other Focal Therapies? Laurence Klotz, MD
10:07-10:30 a.m.	Interactive Patient Cases, Panel Discussion, Abstracts, and Monday Morning Practice Change

Time	Program
	Discussion Leader: David Albala, MD
10:30 a.m.-3:30 p.m.	Free Time
3:30-4:15 p.m.	Mid-Day Industry Symposium Sponsored by: Bayer Suggested alignment: localized disease, active surveillance, focal therapy, imaging, or genomic risk stratification
4:15-5:00 p.m.	SESSION 3: PRECISION ONCOLOGY - WHICH TESTS ACTUALLY CHANGE MANAGEMENT? MODERATOR: Matthew Cooperberg, MD
4:15-4:20 p.m.	Slido Questions and Audience Baseline Polling
4:20-4:28 p.m.	NGS Testing in Advanced Prostate Cancer: Opening the Door to Precision Oncology Jose De La Cerda, MD
4:28-4:36 p.m.	Germline Testing Guideline Update: Who, When, and How? Gordon Brown, DO
4:36-4:44 p.m.	Predictive Tests Beyond NGS and IHC: What Else Is Ready for Practice? Matthew Cooperberg, MD
4:44-5:00 p.m.	Interactive Cases, Panel Discussion, Abstracts, and Monday Morning Practice Change Discussion Leader: Gordon Brown, DO
5:00-5:45 p.m.	Exhibit Hall Break
5:45-6:00 p.m.	AUA PRESIDENTIAL ADDRESS The Future of Urology and Prostate Cancer Care: A Presidential Perspective Eugene Y. Rhee, MD
6:00-7:00 p.m.	SESSION 4: CHOOSING THE RIGHT LOCAL THERAPY - HAS THE PENDULUM SWUNG TOO FAR? MODERATOR: James Eastham, MD
6:00-6:05 p.m.	Slido Questions and Audience Baseline Polling
6:05-6:13 p.m.	Emerging Technologies to Improve Robotic Prostatectomy Robert E. Reiter, MD
6:13-6:21 p.m.	What Is Modern Radiation Therapy? Technique, Fields, Nodes, and ADT Duration Peter Orio, MD
6:21-6:29 p.m.	Telesurgery: Where Are We Today? David Albala, MD
6:29-6:37 p.m.	Evaluating Biochemical Recurrence After Radiation Failure James Eastham, MD
6:37-6:45 p.m.	Focal Therapy: Uses, Misuses, and the TULSA Question Laurence Klotz, MD
6:45-7:00 p.m.	Interactive Patient Cases, Panel Discussion, Abstracts, and Monday Morning Practice Change Discussion Leader: Jonathan Henderson, MD
7:00-8:30 p.m.	Industry Night - Snowspell Apres Bar/Tent

Monday, January 11, 2027

*Please note: Topics and Speakers are subject to change.

Time	Program
6:15 a.m.-3:30 p.m.	Meeting Registration / Information
6:15-6:45 a.m.	Coffee in the Exhibit Hall
6:45-7:45 a.m.	SESSION 5: CURATIVE-INTENT THERAPY FOR INTERMEDIATE- AND HIGH-RISK DISEASE MODERATOR: Peter Orio, MD
6:45-6:50 a.m.	Slido Questions and Audience Baseline Polling
6:50-7:05 a.m.	SOA: Multimodal Curative-Intent Therapy in 2027 - Surgery, Radiation, Systemic Therapy, and Sequencing Peter Orio, MD
7:05-7:13 a.m.	Advanced Imaging for Surgical Planning Will Parker, MD

Time	Program
7:13-7:21 a.m.	PROTEUS: Implications for High-Risk Management and Neoadjuvant Therapy Isaac Kim, MD
7:21-7:29 a.m.	MRI and PSMA PET as Biomarkers for Diagnosis and Treatment Planning Robert E. Reiter, MD
7:29-7:45 a.m.	Interactive Patient Cases, Panel Discussion, Abstracts, and Monday Morning Practice Change Discussion Leader: David Morris, MD
7:45-8:45 a.m.	Industry Breakfast Symposium Sponsored by: Novartis Suggested alignment: high-risk localized disease, neoadjuvant therapy, imaging, radiation, or treatment intensification
8:45-9:15 a.m.	Exhibit Hall
9:15-10:30 a.m.	SESSION 6: CAN WE CURE OLIGOMETASTATIC PROSTATE CANCER? MODERATOR: Gennady Bratslavsky, MD
9:15-9:20 a.m.	Slido Questions and Audience Baseline Polling
9:20-9:35 a.m.	SOA: Oligometastatic Disease in 2027 - Curative Intent or Better Disease Control? Gennady Bratslavsky, MD
9:35-9:43 a.m.	Very-High-Risk and Oligometastatic Intensification Gordon Brown, DO
9:43-9:51 a.m.	Should We Treat Oligometastatic Disease as Metastatic - and When Can We De-intensify? Tian Zhang, MD
9:51-9:58 a.m.	Is There a Place for ADT-Sparing Approaches? Sagar Patel, MD
9:59-10:30 a.m.	Interactive Patient Cases, Panel Discussion, Abstracts, and Monday Morning Practice Change Discussion Leader: Isaac Kim, MD
10:30 a.m.-3:30 p.m.	Free Time
3:30-4:15 p.m.	Mid-Day Industry Symposium Sponsored by: Johnson & Johnson Suggested alignment: oligometastatic disease, biochemical recurrence, radioligand therapy, or metastatic intensification
4:15-5:30 p.m.	SESSION 7: ARE WE OVERTREATING OR UNDERTREATING METASTATIC HORMONE-SENSITIVE DISEASE? MODERATOR: Andrew Hahn, MD
4:15-4:20 p.m.	Slido Questions and Audience Baseline Polling
4:20-4:35 p.m.	SOA: Intensification in 2027 - Moving From Doublets to Triplets and Beyond Andrew Hahn, MD
4:35-4:43 p.m.	How Emerging Immunotherapies May Affect Urologist and Radiation Oncologist Planning Susan Slovin, MD
4:43-4:51 p.m.	Does SPOP Biology Change Treatment Decisions? Jake Orme, PA-C
4:51-4:59 p.m.	Practical De-intensification Protocols in mHSPC Gennady Bratslavsky, MD
4:59-5:07 p.m.	Building a Community Multidisciplinary Advanced Prostate Cancer Program Jeffrey Spier, MD
5:07-5:30 p.m.	Interactive Patient Cases, Panel Discussion, Abstracts, and Monday Morning Practice Change Discussion Leader: Scott Sellinger, MD
5:30-7:00 p.m.	Networking Reception in the Exhibit Hall

Tuesday, January 12, 2027

*Please note: Topics and Speakers are subject to change.

Time	Program
6:30-10:30 a.m.	Meeting Registration / Information
6:30-6:45 a.m.	Coffee in the Exhibit Hall
6:45-8:00 a.m.	SESSION 8: mCRPC - WHAT COMES NEXT BEYOND THE AR PATHWAY? MODERATOR: Scott Sellinger, MD

Time	Program
6:45-6:50 a.m.	Slido Questions and Audience Baseline Polling
6:50-7:05 a.m.	SOA: What Can We Target Outside the Androgen Receptor Pathway? Tian Zhang, MD
7:05-7:13 a.m.	Can We Still Keep the AR Pathway at the Center of mCRPC Treatment? Andrew Hahn, MD
7:13-7:21 a.m.	Can Urologists Manage ARPI Failure? Jason Hafron, MD
7:21-7:29 a.m.	Is Prostate Cancer Really a Cold Tumor? Susan Slovin, MD
7:29-7:37 a.m.	Theranostics and AI: What Is Ready for Practice? Travis Mendel, MD
7:37-8:00 a.m.	Interactive Patient Cases, Panel Discussion, Abstracts, and Monday Morning Practice Change Discussion Leader: David Morris, MD
8:00-8:45 a.m.	Industry Breakfast Symposium Sponsored by: Astellas Pfizer Suggested alignment: mCRPC, ARPI failure, theranostics, immunotherapy, or emerging mechanisms
8:45-9:30 a.m.	SESSION 9: HOLISTIC HEALTH - PROTECTING THE PATIENT WHILE TREATING THE CANCER MODERATOR: David Morris, MD
8:45-8:50 a.m.	Slido Questions and Audience Baseline Polling
8:50-9:05 a.m.	SOA: PC360 Update - Care Teams to Reduce Cardiovascular and Metabolic Toxicity Jason Hafron, MD
9:05-9:13 a.m.	ADT-Related Cardiovascular Toxicity: Does Mechanism of Action Matter? Sagar Patel, MD
9:13-9:21 a.m.	Lesser-Discussed Sexual Side Effects of Curative-Intent Therapy Will Parker, MD
9:21-9:30 a.m.	Interactive Case Discussion and Monday Morning Practice Change Discussion Leader: Jose De La Cerda, MD
9:30-10:15 a.m.	SESSION 10: SURVIVORSHIP - BUILDING THE LIFETIME CARE TEAM MODERATOR: Jeffrey Spier, MD
9:30-9:35 a.m.	Slido Questions and Audience Baseline Polling
9:35-10:00 a.m.	Panel: Developing APP-Led Care Teams - Education, Empowerment, Scope, and Implementation Diane Newman, DNP; Jeffrey Spier, MD; Jake Orme, PA-C
10:00-10:08 a.m.	Prostate Health and Personal Longevity: What Have We Learned? Laurence Klotz, MD
10:08-10:25 a.m.	Interactive Patient Cases, Panel Discussion, Abstracts, and Monday Morning Practice Change Discussion Leader: Sherif Gamie, MD
10:25-10:30 a.m.	Conclusion, Key Practice Changes, and Closing Remarks E. David Crawford, MD